200 related articles for article (PubMed ID: 27016470)
1. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art.
Marcsisin SR; Reichard G; Pybus BS
Pharmacol Ther; 2016 May; 161():1-10. PubMed ID: 27016470
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.
Jin X; Potter B; Luong TL; Nelson J; Vuong C; Potter C; Xie L; Zhang J; Zhang P; Sousa J; Li Q; Pybus BS; Kreishman-Deitrick M; Hickman M; Smith PL; Paris R; Reichard G; Marcsisin SR
Malar J; 2016 May; 15(1):280. PubMed ID: 27188854
[TBL] [Abstract][Full Text] [Related]
3. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6.
Pybus BS; Marcsisin SR; Jin X; Deye G; Sousa JC; Li Q; Caridha D; Zeng Q; Reichard GA; Ockenhouse C; Bennett J; Walker LA; Ohrt C; Melendez V
Malar J; 2013 Jun; 12():212. PubMed ID: 23782898
[TBL] [Abstract][Full Text] [Related]
4. Pathway-specific inhibition of primaquine metabolism by chloroquine/quinine.
Fasinu PS; Tekwani BL; Avula B; Chaurasiya ND; Nanayakkara NP; Wang YH; Khan IA; Walker LA
Malar J; 2016 Sep; 15(1):466. PubMed ID: 27618912
[TBL] [Abstract][Full Text] [Related]
5. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics.
Potter BM; Xie LH; Vuong C; Zhang J; Zhang P; Duan D; Luong TL; Bandara Herath HM; Dhammika Nanayakkara NP; Tekwani BL; Walker LA; Nolan CK; Sciotti RJ; Zottig VE; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Marcsisin SR
Antimicrob Agents Chemother; 2015 Apr; 59(4):2380-7. PubMed ID: 25645856
[TBL] [Abstract][Full Text] [Related]
6. Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
Baird JK; Battle KE; Howes RE
Malar J; 2018 Jan; 17(1):42. PubMed ID: 29357870
[TBL] [Abstract][Full Text] [Related]
7. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
Vuong C; Xie LH; Potter BM; Zhang J; Zhang P; Duan D; Nolan CK; Sciotti RJ; Zottig VE; Nanayakkara NP; Tekwani BL; Walker LA; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Smith B; Marcsisin SR
Antimicrob Agents Chemother; 2015 Jul; 59(7):3864-9. PubMed ID: 25870069
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.
Chamchoy K; Sudsumrit S; Thita T; Krudsood S; Patrapuvich R; Boonyuen U
PLoS Negl Trop Dis; 2022 Dec; 16(12):e0010986. PubMed ID: 36508454
[TBL] [Abstract][Full Text] [Related]
9. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
[TBL] [Abstract][Full Text] [Related]
10.
Pett H; Bradley J; Okebe J; Dicko A; Tiono AB; Gonçalves BP; Stone W; Chen I; Lanke K; Neuvonen M; Mustaniemi AL; Eziefula AC; Gosling R; D'Alessandro U; Drakeley C; Niemi M; Bousema T
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383656
[TBL] [Abstract][Full Text] [Related]
11. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.
Marcsisin SR; Sousa JC; Reichard GA; Caridha D; Zeng Q; Roncal N; McNulty R; Careagabarja J; Sciotti RJ; Bennett JW; Zottig VE; Deye G; Li Q; Read L; Hickman M; Dhammika Nanayakkara NP; Walker LA; Smith B; Melendez V; Pybus BS
Malar J; 2014 Jan; 13():2. PubMed ID: 24386891
[TBL] [Abstract][Full Text] [Related]
12. Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population.
Spring MD; Sousa JC; Li Q; Darko CA; Morrison MN; Marcsisin SR; Mills KT; Potter BM; Paolino KM; Twomey PS; Moon JE; Tosh DM; Cicatelli SB; Froude JW; Pybus BS; Oliver TG; McCarthy WF; Waters NC; Smith PL; Reichard GA; Bennett JW
J Infect Dis; 2019 Oct; 220(11):1761-1770. PubMed ID: 31549155
[TBL] [Abstract][Full Text] [Related]
13. Primaquine revisited six decades after its discovery.
Vale N; Moreira R; Gomes P
Eur J Med Chem; 2009 Mar; 44(3):937-53. PubMed ID: 18930565
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.
Chen N; Dowd S; Gatton ML; Auliff A; Edstein MD; Cheng Q
Malar J; 2019 Apr; 18(1):140. PubMed ID: 30999967
[TBL] [Abstract][Full Text] [Related]
15. Enantioselective metabolism of primaquine by human CYP2D6.
Fasinu PS; Tekwani BL; Nanayakkara NP; Avula B; Herath HM; Wang YH; Adelli VR; Elsohly MA; Khan SI; Khan IA; Pybus BS; Marcsisin SR; Reichard GA; McChesney JD; Walker LA
Malar J; 2014 Dec; 13():507. PubMed ID: 25518709
[TBL] [Abstract][Full Text] [Related]
16. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Bennett JW; Pybus BS; Yadava A; Tosh D; Sousa JC; McCarthy WF; Deye G; Melendez V; Ockenhouse CF
N Engl J Med; 2013 Oct; 369(14):1381-2. PubMed ID: 24088113
[No Abstract] [Full Text] [Related]
17. Genetic Variation of
Stewart AGA; Zimmerman PA; McCarthy JS
Front Pharmacol; 2021; 12():784909. PubMed ID: 34899347
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes.
Ganesan S; Tekwani BL; Sahu R; Tripathi LM; Walker LA
Toxicol Appl Pharmacol; 2009 Nov; 241(1):14-22. PubMed ID: 19616568
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.
Milner EE; Berman J; Caridha D; Dickson SP; Hickman M; Lee PJ; Marcsisin SR; Read LT; Roncal N; Vesely BA; Xie LH; Zhang J; Zhang P; Li Q
Malar J; 2016 Dec; 15(1):588. PubMed ID: 27923405
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation.
Saito T; Gutiérrez Rico EM; Kikuchi A; Kaneko A; Kumondai M; Akai F; Saigusa D; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2018 Dec; 33(6):250-257. PubMed ID: 30366777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]